Low expression of FANCF is known to lead to FANCD2 ubiquitin inactivation and dysfunction of the FA/BRCA pathway, which promote the sensitivity of tumor cells to DNA cross-linking agents, such as melphalan, cisplatin, and mitomyclin C in gliomas, myelomas, and ovarian cancers[18], [19], [20], [21]. This evidence concerns the gene FANCA and neoplasm.